New immune cell therapy targets Hard-to-Treat KRAS cancers in early trial
NCT ID NCT06546150
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 12 times
Summary
This early-phase trial tests a new treatment called RE002 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The treatment uses specially designed immune cells (T cells) to attack the cancer. About 30 adults whose cancer has not responded to standard therapies will receive the injection. The main goal is to see if the tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact
Conditions
Explore the condition pages connected to this study.